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Abstract
The b2-adrenergic receptor (b2AR) agonists with reduced tachyphylaxis may offer new therapeutic agents with improved
tolerance profile. However, receptor desensitization assays are often inferred at the single signaling molecule level, thus
ligand-directed desensitization is poorly understood. Here we report a label-free biosensor whole cell assay with
microfluidics to determine ligand-directed desensitization of the b2AR. Together with mechanistic deconvolution using
small molecule inhibitors, the receptor desensitization and resensitization patterns under the short-term agonist exposure
manifested the long-acting agonism of salmeterol, and differentiated the mechanisms of agonist-directed desensitization
between a full agonist epinephrine and a partial agonist pindolol. This study reveals the cellular mechanisms of agonist-
selective b2AR desensitization at the whole cell level.
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Introduction
The b2-adrenergic receptor (b2AR) is involved in controlling
smooth muscle relaxation in the airways and the vasculature, and
in regulating many other physiologically important processes [1–
4]. b2AR selective agonists are the first-line medications for relief
of life-threatening bronchospasm, the hallmark feature of asthma
and chronic obstructive pulmonary disease. However, prolonged
or repeated use of current b2-agonist drugs leads to loss of their
effects, a pervasive phenomenon termed tachyphylaxis, refracto-
riness, or desensitization [5,6]. b2-agonists with reduced tachy-
phylaxis are postulated to lead to improved tolerance profiles, thus
therapeutically advantageous [7]. Molecular pharmacology assays
have advanced our understanding in the molecular mechanisms of
receptor desensitization and resensitization [7,8]. However,
comprehension about how receptor desensitizes and resensitizes
at the systems level still lags behind, mostly due to lack of assays
that not only effectively detect cell signaling at the whole cell or
pathway level, but also enable mechanistic deconvolution. The
molecular assays often have low temporal resolution, and receptor
desensitization is mostly inferred at the single signaling molecule
level. Physiological assays do describe receptor desensitization at
the systems level, but the resultant hemodynamic parameters are
too complex to derive mechanistic descriptions of receptor
desensitization.
Resonant waveguide grating (RWG) biosensor is a label-free
optical biosensor that has been shown to be able to non-invasively
measure receptor signaling and ligand pharmacology in live cells
[9–12]. The resultant signal, termed as dynamic mass distribution
(DMR), is an integrated and whole cell response that reflects
signaling pathway(s) involved downstream the receptor activation
[13–15]. However, in typical biosensor cellular assays a ligand is
introduced once using a pipetting system and cells are continu-
ously exposed to the ligand, thus creating a static and sustained
stimulation scheme [16]. Such an assay format may mask certain
biased activities of various ligands. Given the pleiotropic pathways
of b2AR signaling [8] and the ability of distinct agonists to stabilize
different active conformations of the receptor [17–19], it is
postulated that distinct agonist-activated conformations could
result in different molecular mechanisms of receptor desensitiza-
tion [20]. Herein, using the b2AR in A431 cells as a model, we
attempt to elucidate the mechanisms of b2AR desensitization and
resensitization at the whole cell level, and to characterize the
agonist-selective desensitization of the b2AR using a microfluidic
biosensor system.
Results
Characteristics of microfluidic biosensor system
The microfluidic biosensor system contains three key compo-
nents: a 464 array of functional RWG biosensors, a microfluidic
device, and a label-free imager. The biosensor array was made
onto a glass substrate using a microfabrication process developed
in house [21], each biosensor having a dimension of 2 mm62m m
and the array having a footprint that is compatible to a standard
384-well microplate. The microfluidic device contains a 464 array
of microfluidic chambers, each having three inlets and one outlet,
and the microchamber array covering 468 array of biosensors so
only one biosensor is centered in each microchamber and the
adjacent biosensor is sacrificed. After assembled onto the substrate,
syringe pumps were connected to the inlets to deliver solutions at a
controlled flow rate. The distance from an inlet to the outlet is
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the microchannel 200 mm (Fig. 1a). The total volume required to
fill up a chamber is 6 ml.
The imager is based on a swept wavelength interrogation
detection scheme, which uses an expanded beam from a tunable
laser light source to simultaneously illuminate at normal incident
angle the biosensor array [22]. This imager has a spatial resolution
of 25 mm and a temporal resolution of 3 sec.
To estimate the shear stress inside the microfluidic chamber we
approximated the flow profile in the middle of the chambers by
parallel-plate Poiseuille flow [23]. Thus, the fluidic shear on the
cells can be modeled by assuming that it would be equal the shear
stress s at the wall between parallel plates under parabolic flow
[22]:
s~
6mQ
h2w
where m is the fluid viscosity, Q the fluid flow rate, h the chamber
height, and w the chamber width. This does not account for
changes in flow due to the presence of the adherent cells, but it
should be a reasonable approximation because w/h is large [25]
and cell layer is only 2–4 mm high. Considering the current
configurations wherein Q is 1 ml/min, m<10
23 Pa?s, h=0.2 mm,
and w=5 mm, we estimated that a wall shear stress s is about
5610
24 Pa, or a shear force is about 5610
23 dyn/cm
2. Such a
low shear force is well below physiological values of 0.5–2 Pa, as
well as those commonly used to cause the activation of selective
signaling cascades such as extracellular signal-regulated kinases
(ERKs) and N-terminal jun kinase in certain cells [24–27].
Potency of the b2AR agonists to trigger DMR signals in
A431 cells
Based on known agonism activity and lipophilicity, four b2-
agonists were chosen to characterize the ligand-selective desensi-
tization in A431, a human epidermoid carcinoma cell line that
endogenously expresses b2AR, but not other adrenergic receptors
[28]. Both epinephrine and salbutamol are hydrophilic agonists,
while pindolol is a moderately lipophilic partial agonist, and
salmeterol is a lipophilic long-acting agonist (Fig. 1b). DMR assays
under the static stimulation condition suggest that a single EC50
was obtained for epinephrine (0.0760.03 nM), S(-)pindolol
(0.0460.02 nM), and salbutamol (0.9060.15 nM) (n=3). How-
ever, salmeterol led to a biphasic dose response with two separated
EC50 (0.260.04 nM and 155623 nM, respectively) (n=3). These
results were consistent with our previous study [29]. Thus we
chose the 16 EC100 dose for each agonist to study receptor
desensitization. The dose was 2 nM, 5 nM, 10 nM, and 100 nM,
for epinephrine, pindolol, salbutamol, and salmeterol, respectively.
Epinephrine stimulation duration dependent signaling of
the b2AR
Under the static stimulation condition epinephrine of 2 nM
induced a DMR that consists of a rapid negative-DMR (N-DMR),
a succeeding positive-DMR (P-DMR) leading to a stably elevated
level for ,2 hrs, followed by a slowly decayed DMR to another
elevated plateau (Fig. 2a). The sustained stimulation with
epinephrine under the shear flow led to almost identical DMR
(Fig. 2b). However, under pulse stimulation conditions epineph-
rine resulted in clear agonist exposure time dependent DMR
signals (Fig. 2b and c), but whose persistences were similar to those
under static stimulation condition. Interestingly, the pulse
stimulation split the single P-DMR into a biphasic event: a rapid
early P-DMR followed by a late P-DMR. Such an alteration in
DMR characteristics suggests that the activation of the b2AR by
epinephrine leads to multiple pathways and certain cell signaling
events require persistent agonist occupancy. Furthermore, results
also showed that regardless of exposure time the epinephrine
DMR remained at the elevated level for at least 2 hrs after agonist
removal, suggesting that once the b2AR signaling propagates, it
remains committing to regulate the whole cell response.
Since the epinephrine DMR was found to be sensitive to the
agonist exposure time, the degrees of receptor internalization
under different stimulation schemes were examined. Considering
the slow kinetics of receptor internalization, all cells were
examined 30 min later since the epinephrine exposure started.
Results showed that similar to unstimulated cells, the b2AR mostly
remained at the cell surface in the 1 min pulse stimulated cells
(Fig. 3a). The 2 min pulse stimulation caused small number of
receptors internalized (Fig. 3b). Receptor internalization became
obvious in the 5 min pulse stimulated cells (Fig. 3c), and mostly
completed in the cells treated continuously with epinephrine for
30 min (Fig. 3d). Thus, this is a clear negative correlation between
the receptor internalization and the occurrence of the early P-
DMR event. This is consistent with our previous finding that
b2AR internalization is a negative contributor to the epinephrine
P-DMR event [29].
Figure 1. A microfluidic RWG biosensor array for characterizing
ligand-directed desensitization of the b2-adrenergic receptor.
(a) Schematic of the biosensor microchamber, wherein an agonist
solution, 2 ml in total, is perfused at a flow rate of 1 ml/min between two
perfusion steps with the assay buffer, thus creating 2 min pulse
stimulation to the cells located within the detection area (black box).
During the time the agonist solution passing through the micro-
chamber, small diffusion occurs. Since the detection area (0.2 mm) is
smaller than the width of the agonist solution (,2 mm for the 2 min
pulse stimulation), the agonist concentration exposed to the cells
within the detection area is considered to be constant. The white box
indicates the location of the biosensor. (b) Structures of four b2-agonists
examined.
doi:10.1371/journal.pone.0019282.g001
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b2AR activation, we were interested in the impacts of agonist
exposure time on ERK1/2 phosphorylation. Similar to internali-
zation, pERK level was measured 30 min later since the stimulation
started regardless ofagonist exposuretime.Immunoblottingshowed
that all stimulations resulted in moderate increase in pERK, but the
pulse stimulations led to more sustained pERK (Fig. 3e). Further-
more, the co-incubation with an ERK inhibitor, Ro31-8220,
blocked the epinephrine-induced ERK activation. Taken together,
these results suggest that the b2AR signaling is sensitive to the
duration of epinephrine occupancy, and certain pathways down-
stream the receptor is persistent after epinephrine removal.
Epinephrine induced desensitization and resensitization
of the b2AR signaling under different stimulation
conditions
Desensitization and resensitization of the b2AR signaling caused
by epinephrine was then examined under different exposure times.
Results showed that the desensitization of the b2AR signaling is also
dependent on the epinephrine exposure time. When cells were
exposed to 2 nM epinephrine for a short period of time (1 min,
2 min or 5 min), the cells still responded to the second epinephrine
stimulation but with a suppressed DMR signal (Fig. 4a), suggesting
that epinephrine removal caused resensitization of the b2AR
signaling. Conversely, under the two sustained stimulation condi-
tions (i.e., static and continuous flow) the cells completely lost their
responsiveness to the second stimulation (Fig. 4b). These results
suggest that the b2AR signaling at the whole cell level is desensitized
even when the receptor occupancy by epinephrine is low.
To examine the cellular mechanisms of b2AR desensitization
and resensitization, several small molecule inhibitors were used.
Results showed that these inhibitors impact differently the DMR
pattern to repeated epinephrine stimulations (Fig. 4c and Fig. 4d).
For the 2
nd epinephrine stimulation induced DMR, the DMR
remained unchanged by PP1 and Ro31-8220, but was slightly
suppressed by H-89. The most notable is that dynasore
potentiated the DMR, while the co-presence of dynasore with
PP1, but not H-89, further increased the DMR. PP1 is a known
Src inhibitor, H-89 is a PKA inhibitor, and dynasore is a dynamin
inhibitor. These results suggest that dynamin- and Src-regulated
processes are important to the epinephrine mediated desensitiza-
tion and resensitization of the b2AR.
Agonist-directed desensitization of the b2AR signaling at
the whole cell level
Next, agonist-selective desensitization was examined. The pulse
stimulation duration was set to be 2 min for all. Results showed
Figure 2. The epinephrine DMR in quiescent A431 cells is
sensitive to stimulation duration. (a) static and sustained
stimulation within 4 hrs, the buffer induced response was included as
a negative control; (b) sustained stimulation with perfusion, in
comparison with static and sustained stimulation within 40 min; (c)
pulse stimulation conditions (1 min, 2 min, and 5 min) followed by
continuous perfusion with the assay buffer. (d) The amplitudes of N-
DMR, early P-DMR (8 min post stimulation) and the P-DMR in total
(30 min post stimulation) for the epinephrine DMR as a function of
stimulation conditions. Epinephrine dose was 2 nM for all. The cells
were monolayer under all conditions. The standard deviation represents
at least 3 replicates in measurements.
doi:10.1371/journal.pone.0019282.g002
Figure 3. Receptor internalization and ERK1/2 phosphorylation
are dependent on the agonist exposure time. (a)–(d) Confocal
images of cells after immunostained with anti-b2AR. The cells were first
stimulated with 2 nM epinephrine for 1 min (a), 2 min (b), 5 min (c) and
30 min (d). After epinephrine removal, the cells were further incubated
in medium at 37uC for 29 min (a), 28 min (b), 25 min (c) and 0 min (d),
respectively, such that equal time post stimulation was achieved for all.
The staining was performed using anti-b2AR antibody and Alexa Fluor
488 goat anti-rabbit antibody. The nuclei were stained with DAPI.
Confocal microscopy images were acquired on Zeiss confocal laser
scanning microscope (oil-immersion, 636objective). The green color is
from the b2AR, the blue from the nuclei. (e) The agonist exposure time
and Ro31-8220 sensitivity of pERK stimulated by epinephrine in A431
cells. The cells were incubated with the vehicle (0 min) or 2 nM
epinephrine for a specific time (1 min, 2 min, 30 min), followed by
further incubation at 37uC for another time to ensure all reach 30 min
post simulation. Ro31-8220 when used was presented throughout the
incubation. Equal amounts of cell lysate were separated by SDS-PAGE
and analyzed for pERK by Western blotting. Equivalent gel loading was
confirmed by probing with antibodies against GAPDH.
doi:10.1371/journal.pone.0019282.g003
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a separation of the single phase P-DMR under the sustained
stimulation into the biphasic P-DMR events (Fig. 5a). Pindolol led
to a DMR similar to that obtained under the sustained stimulation,
but with a slower kinetics (Fig. 5b). Conversely, salmeterol led to a
DMR identical to that obtained under the sustained stimulation
(Fig. 5c). Furthermore, the pulse stimulation also caused an
agonist-dependent receptor desensitization and resensitization
pattern (Fig. 5d). Under the pulse stimulation condition, both
salmeterol and pindolol caused complete desensitization to
repeated epinephrine stimulation, while epinephrine and salbuta-
mol caused partial desensitization. The resensitization degree is
higher for epinephrine than salbutamol. Thus, these results suggest
that the microfluidic biosensor differentiates ligand-directed
desensitization of the b2AR.
The desensitization mechanism caused by pindolol was further
examined, since it was unexpected that pindolol behaved similarly
to salmeterol, both of which caused complete desensitization to the
repeated stimulation with epinephrine. Results showed that the
pindolol DMR itself was found to be potentiated by PP1 and
Ro31-8220, but suppressed by H-89 (Fig. 6a). However, the 2
nd
epinephrine stimulation induced DMR displayed different pat-
terns – the epinephrine DMR was the greatest in the presence of
PP1, followed by H-89.Ro31-8220 (Fig. 6b). These results
suggest that both Src and PKA are important in regulating the
desensitization caused by pindolol.
To understand the ligand-selective receptor desensitization, we
determined relative efficacy of the b2AR agonists in DMR assays
using the Black and Leff model of operational agonism [30]. It
defines agonist [A] response as [31]
Response~
½A :t:Emax
½A (tz1)zKA
Where [A] is the agonist concentration, Emax the maximal response
of A431 cell, KA the equilibrium dissociation constant of the ligand,
and t an efficacy term equal to the ratio of receptor density (RT)t o
Figure 4. The desensitization and resensitization patterns of
quiescent A431 cells induced by epinephrine is sensitive to
stimulation duration and several inhibitors. (a) The DMR signals
upon repeated stimulations with epinephrine. After initial baseline
(,2 min), the cells were first stimulated with epinephrine (1
st EPI) for
three different durations (1 min, 2 min, or 5 min), followed by
perfusion with the assay vehicle for ,35 min, and finally stimulated
again with a continuous flow of epinephrine (2
nd EPI) for ,30 min. (b)
The amplitudes of both N-DMR and P-DMR of the 2
nd EPI induced
DMR as a function of the 1
st stimulation conditions. (c) The
epinephrine DMR in the absence and presence of dynasore. The cells
were first stimulated with epinephrine for 2 min (1
st EPI) in the
presence and absence of dynasore, followed by perfusion with the
assay buffer in the absence and presence of dynasore, respectively.
Afterwards, all the cells were repeatedly stimulated with epinephrine
in the absence of dynasore (2
nd EPI). (d) The amplitudes of both N-
DMR and P-DMR of the 2
nd EPI induced DMR as a function of
inhibitors. Each inhibitor or their combinations were assayed in a
manner similar to dynasore. The flow rate was 1 ml/min under all
conditions. Inhibitor concentrations were 5 mM, 10 mM, 10 mM, and
50 mM for H-89, Ro31-8220, PP1, and dynasore, respectively.
Epinephrine dose was 2 nM for all. n=3.
doi:10.1371/journal.pone.0019282.g004
Figure 5. The DMR signals induced by distinct b2AR agonists
under distinct conditions. (a) salbutamol, (b) pindolol, and (c)
salmeterol, under the 2 min pulse stimulation in comparison with the
sustained stimulation conditions. (d) The amplitudes of both N-DMR
and P-DMR (30 min post stimulation) of the 2
nd epinephrine stimulation
induced DMR as a function of different agonists. For receptor
desensitization studies, two steps were separated by ,45 min. The
initial stimulation duration with an agonist was 2 min, while the second
stimulation was continuous. The concentration was 2 nM, 5 nM, 10 nM,
and 100 nM for epinephrine, pindolol, salbutamol, and salmeterol,
respectively. n=3.
doi:10.1371/journal.pone.0019282.g005
Figure 6. The DMR patterns of cells upon repeated stimulation
with pindolol and epinephrine. Step 1: 2 min pulse stimulation in
the absence and presence of an inhibitor, followed by perfusion with
the assay buffer in the absence and presence of the respective inhibitor;
and Step 2: continuous exposure to 2 nM epinephrine using perfusion.
(a) DMR signals, and (b) DMR characteristics, later of which the P-DMR of
the 1
st pindolol-induced DMR, and both N-DMR and P-DMR of the 2
nd
EPI induced DMR were plotted as a function of inhibitors. The flow rate
was 1 ml/min under all conditions. n=2 to 4.
doi:10.1371/journal.pone.0019282.g006
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receptor complex. The KA values of epinephrine, pindolol,
salbutamol and salmeterol were obtained from literature, and
were 741.3, 0.6, 977.2, and 0.5 nM, respectively [32]. Fitting the
dose-dependent DMR response of each ligand with the opera-
tional mode led to a t value of 79046678, 1.8660.10, 721694,
and 2.4260.14 for epinephrine, pindolol, salbutamol and
salmeterol, respectively. The dose response as a function of
receptor level was then simulated for each agonist using the
operational model (Fig. 7). The reduced spare receptors were used
to mimic desensitization. Results showed that as expected the
apparent potency and efficacy of all agonists decreased as the total
receptors decreased, but different agonists exhibited distinct
sensitivity to the total receptor numbers. Both epinephrine and
salbutamol exhibited higher efficacy and were less sensitive to loss
of receptor than pindolol and salmeterol. Further, the responses of
the b2AR agonists at their original EC100 showed distinct
sensitivity to loss of receptor, with the order of pindolol.salme-
terol.salbutamol.epinephrine (Fig. 8a), while the maximal
achievable responses by pindolol and salmeterol were more
sensitive to loss of receptors than those by epinephrine and
salbutamol (Fig. 8b). This is consistent with our results obtained
under the pulse stimulation condition, when the repeated
stimulation with epinephrine of 2 nM was used as readout of
receptor desensitization and resensitization (Fig. 5d).
Discussion
The present method is greatly different from conventional
receptor desensitization and resensitization studies. First, receptor
desensitization and resensitization was carried out at the whole cell
level enabled by label-free DMR assays, instead of single signaling
molecule(s) downstream the receptor activation. Second, as a step
closer to clinical settings where doses given to patients are based on
functional effect but not receptor occupancy [33,34], we chose
equi-effective doses, instead of doses to achieve equal receptor
occupancy, for the desensitization studies. Third, since the
receptor activation by endogenous agonists often occur under
pulse stimulation conditions (e.g., synaptic transmission) [35], we
chose a pulse stimulation scheme to achieve receptor desensitiza-
tion and a short duration of receptor recovery to study receptor
resensitization. Fourth, the non-invasive and real time kinetic
measures of DMR assays not only allow us track the process of
signaling propagation when stimulation is terminated, but also
make it possible to deconvolute the pathway biased mechanisms of
distinct agonists to cause receptor desensitization.
The RWG biosensor non-invasively monitors a cellular
response and converts it into a biosensor signal, termed DMR.
The DMR is reported as a shift in resonant wavelength (in
picometer). Since the biosensor is sensitive to alterations in local
refractive index which is directly correlated to the density of local
Figure 7. The simulated dose responses of distinct agonists as a function of spare receptors in the cell using the operational model.
(a) epinephrine; (b) pindolol; (c) salbutamol; and (d) salmeterol. The spare receptors were normalized in percentage.
doi:10.1371/journal.pone.0019282.g007
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local biomass within the sensing volume of the biosensor [15].
Combining with chemical biology and conventional cell biology
approaches, we and others have found that DMR faithfully reflects
the early cell signaling pathways downstream of receptor
activation [11]. In our recent and present studies we have found
that for the epinephrine-induced DMR of the b2AR in A431, (1) it
is largely downstream of adenylate cyclase activation [36]; (2) it
involve multiple pathways including Src, PKA-MAPK, and
dynamin [36]; (3) the receptor internalization is a negative
contributor to its P-DMR event in which receptor internalization
slows down its kinetics [29]; (4) the actin remodeling, but to less
extent microtubule remodeling, contributes to its early DMR
event [30]; and (5) other cellular events including the b2AR
activation induced increase in cell adhesion may also contribute to
its DMR.
To study ligand-directed desensitization of the b2AR, we
developed a microfluidic biosensor system. The system enables
precise controls of agonist exposure time and the duration of the
functional recovery of activated receptors with a moderate
throughput (16 independent measurements in parallel). DMR
assays under different conditions revealed two types of b2AR
agonists. Comparing to their respective DMR signals obtained
under two (static and perfusion) sustained stimulation conditions,
the pulse stimulation resulted in more obvious alterations in
characteristics of DMR signals induced by epinephrine and
salbutamol, compared to pindolol or salmeterol. Such different
behaviors appear correlated well with the difference in lipophilicity
of distinct agonists. Unlike epinephrine and salbutamol both of
which are hydrophilic and short-acting agonists, both salmeterol
and pindolol are lipophilic, thus leading to long-acting agonism.
The biosensor cellular assays with microfluidics allow ligand-
directed desensitization to be studied at the whole cell level,
instead of measurements based on single signaling molecules using
conventional assays. Results showed that at the whole cell level the
b2AR signaling is desensitized even at low receptor occupancy by
agonists of high intrinsic efficacy such as epinephrine or
salbutamol. Further, the desensitization and resensitization pattern
was found to depend on the types of agonists and stimulation
conditions. Both pindolol and salmeterol led to complete
desensitization to the repeated stimulation with epinephrine, even
when the initial stimulation duration was short as 2 min. However,
both epinephrine and salbutamol resulted in desensitization
patterns that are dependent on the initial agonist exposure
duration. The shorter the initial stimulation the greater resensi-
tization is. Using small molecule inhibitors, the biosensor cellular
assays with microfluidics also enable mechanistic deconvolution of
signaling pathways that lead to receptor desensitization. Results
showed that the epinephrine pulse stimulation induced desensiti-
zation was sensitive to both Src and dynamin, while the pindolol
pulse stimulation induced desensitization was related to Src and
PKA. Together, these results suggest that the b2AR desensitization
is ligand-selective.
In conclusion, the label-free and microfluidic RWG biosensor
enables precise control the times of both agonist exposure and
functional recovery of the agonist-activated receptors. Using the
endogenous b2AR in A431 as a model, ligand-directed desensi-
tization of the b2AR was manifested – both salmeterol and
pindolol exhibit long-acting agonism, when epinephrine and
salbutamol display short acting agonism. Furthermore, epineph-
rine caused receptor desensitization at the whole cell level via the
dynamin and Src-mediated processes, while pindolol caused
receptor desensitization mostly via PKA and Src. Scaling up the
biosensor system will open new means to screen novel b2-agonists
with reduced tachyphylaxis.
Materials and Methods
Materials
Epinephrine, salmeterol, pindolol and salbutamol were obtained
from Sigma Chemical Co. (St. Louis, MO, USA). PP1, H-89,
Ro31-8220 and dynarose were obtained from Tocris (St. Louis,
MO, USA). Rabbit polyclonal anti-b2AR (#sc-569), mouse
monoclonal anti-pERK1/2 (#sc-81492) and rabbit polyclonal
anti-GAPDH (#sc-25778) antibodies were purchased from Santa
Cruz Biotechnology Inc. (Santa Cruz, CA, USA). Mouse
monoclonal anti-ERK1/2 (#L38C12) was obtained from Cell
Signaling Technology Inc (Danvers, MA). Alexa Fluor 488 goat
anti-rabbit antibody was purchased from Invitrogen (Carlsbad,
CA, USA). EpicH 384-well biosensor microplates and inserts were
obtained from Corning Inc. (Corning, NY, USA). Poly-dimethyl-
siloxane (PDMS) was obtained from Dow Chemical (Midland, MI,
USA).
Figure 8. The simulated sensitivity of distinct agonists to loss of receptors (in percentage). (a) The effect of an EC100 of each agonist
(calculated where the total receptor is unchanged; RT=100) at different receptor numbers. Data were normalized to percentage of the response at
the EC100 where RT=100. (d) The function of Emax achievable by the agonists as receptor loss.
doi:10.1371/journal.pone.0019282.g008
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Soft lithography was used to fabricate the microfluidic biosensor
device using PDMS replicas [37]. Briefly, features on chrome
mask were transferred onto silicon wafers using standard
photolithographic process. The photoresist-defined silicon wafers
were then anisotropically etched to a desired depth in a multiplex
inductively coupled plasma etching system (Surface Technology
Systems, Newport, NJ, USA). After photoresist removal and
overnight coating using trichloro(1H,1H,2H,2H-perfluorooctyl)si-
lane, a PDMS pre-polymer solution containing a mixture (10:1
mass ratio) of PDMS oligomers and a reticular agent (Sylgard
184H Kit, Dow Corning Corp., Midland, MI, USA) was cast onto
the etched silicon wafers and cured at room temperature for about
24 hrs to minimize shrinkage after curing. Next, the PDMS
replicas were carefully peeled away from the silicon wafers.
Finally, after punching inlet and outlet holes, the PDMS replica
was aligned and reversibly bonded onto the top of biosensor
inserts.
Cell culture
Human epidermoid carcinoma A431 cells were obtained from
American Type Cell Culture. The cells were grown in the cell
culture medium (Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 10% fetal bovine serum (FBS), 4.5 g/liter
glucose, 2 mM glutamine, and antibiotics). The native cells were
passed when approaching ,90% confluence with trypin/EDTA
(etthylenediaminetetraacetic acid) to provide new maintenance
cultures on T-75 flasks and experimental cultures on the biosensor
microplates or chambers. The cells up to at least 20 passages are
appropriate for the biosensor cellular assays in our laboratory.
For cell culture within the microfluidic biosensor device, the
device, tubing (Tygon S-54-HL, Saint-Gobain Performance
Plastics, Akron, OH, USA) and syringes (500 ml, gas tight 1700
series, Hamilton, Reno, NV, USA) were sanitized with 70%
ethanol. After sanitization, the microfluidic chambers were filled
with the cell culture media. Cells after harvested using tyrpsiniza-
tion were freshly suspended in the medium. 4610
4 cells suspended
in 6 ml of the medium were injected into each chamber. Cells were
allowed to seed via 30 min incubation at room temperature.
Tubing was then plugged into the microchamber inlets and was
connected to syringes that were connected to a syringe pump
(Model: SP230IW; World Precision Instruments, Sarasota, FL,
USA). To prevent any evaporation, the biosensor device was
maintained within a petri dish with a cover, and extra cell medium
within the dish. Next, the cells were cultured at 37uC under air/
5% CO2 and perfusion of the serum rich media was started at a
flow rate of 5 ml/hr. After overnight culturing, the cells reached a
confluency of about 95%. The cells were then subject to overnight
starvation with the medium without any FBS.
For cell culture under regular Epic biosensor microplates, 20000
cells per well, suspended in the DMEM medium containing 10%
FBS, were directly seeded into the microplates. After overnight
culturing, the cells were subject to 24 hrs starvation using the
serum-free medium.
DMR assays under static stimulation conditions using
EpicH system
EpicH system (Corning Inc., Corning, NY, USA) is a wavelength
interrogation reader system tailored for resonant waveguide
grating (RWG) biosensors in microtiter plates, and used for
DMR assays under static stimulation conditions [21]. This system
consists of a temperature-control unit, an optical detection unit,
and an on-board liquid handling unit with robotics. The detection
unit is centered on integrated fiber optics, and enables kinetic
measures of cellular responses with a time interval of ,15 sec.
After culturing, the cells were washed with the assay buffer (16
HBSS, Hanks’ balanced salt solution, 20 mM Hepes, pH 7.1) and
incubated within the system for about 1 hr. Afterwards a 2-min
baseline was established. Compound solutions were then trans-
ferred into the biosensor wells using the on-board liquid handling
device, and the cell responses were recorded in real time. During
the assay, the compounds added remain inside the wells. All
studies were carried out with at least three replicates, unless
specifically mentioned.
DMR assays under microfluidic environments using a
RWG imager system
A whole microplate RWG biosensor imager system was recently
developed [22]. This system was further modified to increase
spatial resolution as well as to accommodate the reduced footprint
of the current microfluidic biosensor devices. Specifically, a
tunable light source is passed through a polarizer to generate a
polarized light, which is then expanded through optical lens and
mirrors to simultaneously illuminate at a normal incident angle all
biosensors within a microfluidic device. The tunable light source
linearly scans the wavelength range from 826 nm to 838 nm in
every 3 seconds, such that the biosensor array is illuminated and
synchronously imaged by a 140061024 pixel complementary
metal oxide semiconductor camera (Dalsa Inc., Ontario, Canada).
The spectral images are processed online to extract the resonant
wavelengths (in picometer, pm) and their changes over time. In
order to minimize assay variability as well as the impact of time lag
across the biosensor, cells only located within the central area of a
biosensor (0.262 mm) were sampled to generate an averaged
response. For DMR assays under microfluidics, microchambers
with confluent layer of cells after culturing were connected to three
independently operated syringes using Tygon O ` tubing. Initially
cells were perfused with the assay buffer at a flow rate of 1 ml/min
until a baseline signal was established and normalized to zero. By
switching operational pumps cells were then stimulated with a
ligand for a specific period of time, followed by perfusion with the
assay buffer for 40 min to allow functional recovery of activated
receptors. Finally the cells were stimulated again with a continuous
flow of epinephrine solution for 30 min. The three independently
operated inlets allowed us to perform continuous perfusion of cells
during the assay without any abrupt changes of shear stress or
laminar flow perturbation inside the microfluidic chamber.
Receptor internalization assays
A431 cells were grown on glass chamber slides (Nunc,
Rochester, NY). After treatment with epinephrine for a given
period, the agonist solution was replaced with the serum free
medium and further incubated for another specified period at
37uC inside a standard cell culture incubator. The cells were then
fixed with 2% formaldehyde in phosphate buffered saline solution
(PBS), and permeabilized with 0.1% Triton X-100 in PBS. After
blocking using bovine serum at room temperature, cells were
incubated overnight with primary antibody (anti-b2AR antibody)
at 4uC. This was followed by three washing steps with PBS, an
1 hr incubation with Alexa Fluor 488 goat anti-rabbit antibody,
and final washing steps. Then, samples were imbedded in
mounting medium containing DAPI, a nuclei staining agent
(Vector Labs, Burlingame, CA). Confocal microscopy images were
acquired on ZEISS confocal Laser Scanning Microscope (oil-
immersion, 636objective). The digital images were processed with
ImageJ (http://rsbweb.nih.gov/ij/).
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The p44/42 MAP kinases were examined using Western
blotting. Whole cell lysates were prepared for A431. Cells were
either treated or not with epinephrine in the absence and presence
of Ro31-8220 for a specified period, followed by further
incubation at 37uC in the serum free medium for another
specified period. Equivalent gel loading was confirmed by probing
with antibodies against GAPDH. The total ERK1/2 and
phosphorylated ERK1/2 were blotted using respective antibodies.
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